BiotechTube

Aprepitant

ApprovedWithdrawn
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Nausea

Conditions

Nausea, Vomiting

Trial Timeline

— → Sep 1, 2008

NCT ID
NCT00429754

About Aprepitant

Aprepitant is a approved stage product being developed by Merck for Nausea. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00429754. Target conditions include Nausea, Vomiting.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (3)

NCT IDPhaseStatus
NCT00429754ApprovedWithdrawn
NCT01334086Phase 2Completed
NCT01298193ApprovedCompleted

Competing Products

20 competing products in Nausea

See all competitors
ProductCompanyStageHype Score
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
85
Sancuso + IV granisetronKyowa KirinPhase 1
33
granisetron transdermal system + Granisetron IVKyowa KirinPhase 1
33
palonesetronEisaiPhase 2
52
Ondansetron + PalonosetronEisaiPhase 2
52
GranisetronKyowa KirinPhase 3
77
Sancuso + IV granisetronKyowa KirinPhase 1
33
DroperidolKyowa KirinApproved
85
LY3537021 + Placebo + Standard of Care Antiemetic Therapies + Background ChemotherapyEli LillyPhase 2
52
esomeprazoleAstraZenecaPhase 3
77
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + PlaceboMerckPhase 2
52
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue TherapyMerckPhase 3
77
Aprepitant + Aprepitant Placebo + Ondansetron + Dexamethasone + Ondansetron Placebo + Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).MerckApproved
85
Dexamethasone + Aprepitant + Placebo DexamethasoneMerckPre-clinical
23
Comparator: MK0517 + Comparator: ondansetronMerckPhase 3
77
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
85
FosaprepitantMerckPhase 2
52
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonistMerckPhase 3
77
Aprepitant + ScopolamineMerckPre-clinical
23
Fosaprepitant + Dexamethasone + 5HT3MerckPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85